VERITAS IN SILICO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,002 JPY | -1.38% |
|
-13.40% | 0.00% |
| 1 day | -1.38% | ||
| 1 week | -13.40% | ||
| Current month | -8.74% | ||
| 1 month | -9.73% | ||
| 3 months | -44.91% |
1 week
1 000.00
1 223.00
1 month
1 000.001 236.00
Current year
1 000.003 475.00
1 year
1 000.003 475.00
3 years
1 000.003 475.00
5 years
1 000.003 475.00
10 years
1 000.003 475.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shingo Nakamura
FOU | Founder | 52 | 16-11-16 |
| Chief Administrative Officer | 56 | 18-05-31 | |
Takashi Kamimura
COO | Chief Operating Officer | 68 | 17-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Kamimura
COO | Chief Operating Officer | 68 | 17-03-31 |
Shingo Nakamura
FOU | Founder | 52 | 16-11-16 |
| Director/Board Member | 57 | 19-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 1,002 | -1.38% | 60 900 |
| 24-07-02 | 1,016 | -3.33% | 81,800 |
| 24-07-01 | 1,051 | -4.28% | 100,000 |
| 24-06-28 | 1,098 | -8.50% | 159,200 |
| 24-06-27 | 1,200 | +3.72% | 85,900 |
Delayed Quote Japan Exchange, July 03, 2024 at 02:00 am EDT
More quotes
Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 40.05M | |
| +17.72% | 44.87B | |
| -10.33% | 37.8B | |
| +42.32% | 37.61B | |
| +29.36% | 31.32B | |
| -8.44% | 27.4B | |
| +12.45% | 26.32B | |
| +44.19% | 14.07B | |
| +31.93% | 12.5B | |
| -7.67% | 11.23B |
- Stock Market
- Equities
- 130A Stock
